MoonLake Immunotherapeutics (MLTX)
UndervaluedFundamental
32
मूल्य
$11.55
मार्केट कैप
$996M
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 19 सितंबर 2026 with claude-haiku-4-5 — shared with all users
AbbVie's adalimumab (Humira) was the first biologic approved for hidradenitis suppurativa and still defines first-line treatment, while its risankizumab (Skyrizi) competes in psoriatic arthritis — both were used as active reference arms in MoonLake's own trials.
Lilly's ixekizumab (Taltz) is an IL-17A inhibitor prescribed for psoriatic arthritis, axial spondyloarthritis and plaque psoriasis, the rheumatology and dermatology indications sonelokimab is being developed for beyond hidradenitis suppurativa.
Incyte is bringing povorcitinib, an oral JAK1 inhibitor, through late-stage trials in hidradenitis suppurativa, competing for the same patients with a pill rather than an injection.
UCB's bimekizumab (Bimzelx) blocks the same IL-17A and IL-17F cytokines as sonelokimab and is already approved for hidradenitis suppurativa and psoriatic arthritis, the two indications MoonLake is bringing to market.
Novartis sells secukinumab (Cosentyx), the IL-17A inhibitor approved in 2023 for hidradenitis suppurativa and widely used in psoriatic arthritis and axial spondyloarthritis, addressing the same dermatology and rheumatology prescribers MoonLake targets.
बैलेंस शीट और तरलता
राजस्व
0
31/12/2025 को समाप्त वित्त वर्ष
शुद्ध आय
$-227M
31/12/2025 को समाप्त वित्त वर्ष
Free Cash Flow
$-196M
कुल इक्विटी
$304M
कुल देनदारियाँ
$120M
Current Ratio
12.56
Interest Coverage
26.58
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
कोई आय डेटा उपलब्ध नहीं
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$28.54
वर्तमान मूल्य
$11.55
Margin of Safety
+59.5%
Fair Value सीमा
$27.11 - $29.97
इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-74.7%
P/B Ratio
2.33
P/FCF
-
Gross Margin
-
ROIC
-40.1%
लाभप्रदता Radar
मूल्य सृजन (प्रतिस्पर्धी बढ़त)
ROIC
-40.1%
WACC
10.3%
ROIC − WACC
-50.4 pp
ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।
Fundamental विश्लेषण मानदंड
पास (7)
- P/B Ratio 2.33
- Debt/Equity ratio
- Current Ratio
- Interest Coverage
- Low reliance on intangibles
- Analyst Consensus 77% Buy
- Share Dilution 2.3%
फेल (9)
- EPS shows upward trend
- Price CAGR 2.13%
- ROIC -40.1%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -82.7%
- Earnings Surprise avg -2.8%
- Piotroski F-Score 1/9
अनुपलब्ध (11)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- Operating Margin NaN%
- CapEx intensity
- Debt/EBITDA
- Price below Graham Number
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है
संस्थागत होल्डिंग
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Dr. Jorge Santos da Silva Ph.D. | Co-Founder, Interim Chair of the Board & CEO | 48 |
| Dr. Kristian Reich M.D., Ph.D. | Co-Founder & Chief Scientific Officer | 59 |
| Mr. Matthias Bodenstedt | Chief Financial Officer | 37 |
| Mr. Oliver Daltrop Ph.D. | Chief Technical Officer | - |
| Ms. Carla Bretes | Director of Investor Relations & External Communications | - |
| Mr. Nicolas Mosimann Ph.D. | General Counsel | - |
| Joana Cortez | Associate Vice-President of Legal & Compliance | - |
| Tino Anthamatten | Vice President of Marketing, Market Access & Pricing | - |
| Luciana Marques | Associate Vice-President of HR, People and Culture | - |
| Ms. Nuala Brennan | Chief Clinical Development Officer | - |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
दस्तावेज़
- दस्तावेज़ देखें
वार्षिक रिपोर्ट (10-K)
कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।
दाखिल तिथि: 2026-02-25
- दस्तावेज़ देखें
तिमाही रिपोर्ट (10-Q)
पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।
दाखिल तिथि: 2026-08-10
- दस्तावेज़ देखें
विशेष रिपोर्ट (8-K)
किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।
दाखिल तिथि: 2026-09-30
via SEC EDGAR
आय का इतिहास
via SEC EDGAR
Latest News
Recent headlines for MLTX, sourced from Markets Gazette.
- 3/30/2026POSITIVEMoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Immunotherapeutics announced promising Phase 3 results for its lead drug in Hidradenitis Suppurativa (HS), showing a 62% HiSCR75 response rate at Week 40. This durable response rate suggests strong efficacy. Crucially, the company received feedback from the FDA that supports a potential path to filing without requiring additional trials. This significantly de-risks the development timeline and accelerates the path to market. Investors are likely to view this news favorably, anticipating a potential new treatment option and a strong commercial opportunity.
via Markets Gazette